Commenting on the study for heartwire, antiplatelet expert Dr Victor Serebruany (HeartDrug Research, Towson, MD) said: "This is an extremely important paper with a clear clinical message—abrupt ...

Aspirin is considered the cornerstone of secondary prevention of coronary artery disease. However, the evidence supporting aspirin was largely generated before the advent of modern pharmacological and ...

Please provide your email address to receive an email when new articles are posted on . In early 2009, the FDA announced an ongoing safety review of clopidogrel after receiving reports that the use of ...

In January 2008, Dr Steven Steinhubl announced that he was leaving his academic position to join The Medicines Company. Although Steinhubl had no official relationship with the company at the time he ...

You have full access to this article via your institution. The Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis In Myocardial Infarction study (CLARITY-TIMI) 28 trial was an international, ...

A comprehensive analysis of nearly 29,000 patients with coronary artery disease (CAD) suggests that clopidogrel, a commonly prescribed blood thinner, is more effective than aspirin in preventing ...

For decades, aspirin has been the go‑to drug for preventing heart attacks and strokes. But recent research is turning that assumption on its head. Aspirin has been overtaken by another well-known ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In a pooled cohort of the two STOPDAPT-2 trials, among ...

Patients with high-risk features undergoing elective PCI and treated with the more-potent antiplatelet agent ticagrelor (Brilinta; AstraZeneca) instead of clopidogrel fared no better with respect to ...

Ticagrelor may not have an advantage over clopidogrel as part of a dual antiplatelet therapy (DAPT) regimen when it comes to treating ACS patients who have undergone PCI in everyday practice, a large ...

Gaspoz et al. (June 6 issue) 1 present an interesting perspective on the problem of escalating health care costs. Their comparison between the cost effectiveness of aspirin and that of clopidogrel is ...

To the Editor: The conduct of the Clopidogrel and the Optimization of Gastrointestinal Events Trial (COGENT) by Bhatt and colleagues (Nov. 11 issue) 1 is timely. Previous nonrandomized studies have ...